ST. LOUIS, July 23, 2019 /PRNewswire/ -- Centene Corporation
(NYSE: CNC) announced today its financial results for the second
quarter ended June 30, 2019, reporting diluted earnings per
share (EPS) of $1.18, and Adjusted
Diluted EPS of $1.34.
In summary, the 2019 second quarter results were as follows:
Total revenues (in
millions)
|
$
|
18,356
|
|
|
Health benefits
ratio
|
86.7
|
%
|
|
SG&A expense
ratio
|
9.1
|
%
|
|
GAAP diluted
EPS
|
$
|
1.18
|
|
|
Adjusted Diluted EPS
(1)
|
$
|
1.34
|
|
|
Total cash flow
provided by operations (in millions)
|
$
|
917
|
|
|
|
|
|
(1) A full
reconciliation of Adjusted Diluted EPS is shown beginning on page
five of this release.
|
Diluted and Adjusted Diluted EPS for the second quarter of 2019
benefited from solid operating performance across our business
segments, the net impact of the reconciliation of the 2018 risk
adjustment program exceeding our expectations by $0.05 per diluted share and a gain related to the
acquisition of Ribera Salud of
$0.03 per diluted share.
Michael F. Neidorff, Centene's
Chairman, President and Chief Executive Officer, stated, "Our
strong second quarter results demonstrate Centene's favorable
financial and operating momentum. Our pending WellCare
acquisition will bolster and diversify our product offerings,
significantly increase our scale and provide access to new markets
- enhancing Centene's long-term growth outlook."
Second Quarter Highlights
- June 30, 2019 managed care
membership of 15.0 million, an increase of 2.2 million members, or
17%, over June 30, 2018.
- Total revenues for the second quarter of 2019 of $18.4 billion, representing 29% growth compared
to the second quarter of 2018.
- Health benefits ratio (HBR) of 86.7% for the second quarter of
2019, compared to 85.7% in the second quarter of 2018.
- Selling, general and administrative (SG&A) expense ratio of
9.1% for the second quarter of 2019, compared to 9.6% for the
second quarter of 2018.
- Adjusted SG&A expense ratio of 9.0% for the second quarter
of 2019, compared to 9.6% for the second quarter of 2018.
- Diluted EPS for the second quarter of 2019 of $1.18, compared to $0.75 for the second quarter of 2018, an increase
of 57%.
- Adjusted Diluted EPS for the second quarter of 2019 of
$1.34, compared to $0.90 for the second quarter of 2018, an increase
of 49%.
- Operating cash flow of $917
million for the second quarter of 2019, representing 1.9x
net earnings.
Other Events
- In July 2019, our Oregon subsidiary, Trillium Community Health
Plan, was notified by the Oregon Health Authority (OHA) of its
intent to award Trillium an expanded contract to serve as a
coordinated care organization for six counties in the state.
Pending successful completion of OHA's readiness review and
additional contract negotiations, the contract is scheduled to
begin on January 1, 2020.
- In June 2019, our Spanish
subsidiary, Primero Salud, acquired additional ownership in
Ribera Salud, increasing our
ownership in the Spanish healthcare company from 50% to 90%.
- In June 2019, all proposals
regarding the pending acquisition of WellCare Health Plans, Inc.
(WellCare) were approved by Centene and WellCare shareholders.
Accreditations & Awards
- In July 2019, FORTUNE announced
Centene's position of #168 in its annual ranking of the largest
companies globally by revenue.
- In July 2019, Centene was
recognized with a 100 percent score on the Disability Equality
Index (DEI) as one of the Best Places to Work for People with
Disabilities.
- In May 2019, FORTUNE announced
Centene's position of #51 in its annual ranking of America's
largest companies by revenue.
- In May 2019, Centene and several
of its subsidiaries earned Accreditation from NCQA, including
California Health & Wellness and Health Net Community
Solutions.
Membership
The following table sets forth our membership by line of
business:
|
June
30,
|
|
2019
|
|
2018
|
Medicaid:
|
|
|
|
TANF, CHIP &
Foster Care
|
7,388,700
|
|
|
5,852,000
|
|
ABD &
LTSS
|
997,900
|
|
|
874,200
|
|
Behavioral
Health
|
68,800
|
|
|
454,600
|
|
Total
Medicaid
|
8,455,400
|
|
|
7,180,800
|
|
Commercial
|
2,449,400
|
|
|
2,051,700
|
|
Medicare
(1)
|
398,500
|
|
|
343,800
|
|
International
|
463,100
|
|
|
—
|
|
Correctional
|
153,900
|
|
|
157,900
|
|
Total at-risk
membership
|
11,920,300
|
|
|
9,734,200
|
|
TRICARE
eligibles
|
2,855,800
|
|
|
2,851,500
|
|
Non-risk
membership
|
228,100
|
|
|
218,100
|
|
Total
|
15,004,200
|
|
|
12,803,800
|
|
|
(1)
|
Membership includes
Medicare Advantage, Medicare Supplement, Special Needs Plans, and
Medicare-Medicaid Plans (MMP).
|
The following table sets forth additional membership statistics,
which are included in the membership information above:
|
June
30,
|
|
2019
|
|
2018
|
Dual-eligible
(2)
|
600,800
|
|
|
489,500
|
|
Health Insurance
Marketplace
|
1,910,700
|
|
|
1,503,100
|
|
Medicaid
Expansion
|
1,290,200
|
|
|
1,079,700
|
|
|
(2)
|
Membership includes
dual-eligible ABD & LTSS and dual-eligible Medicare membership
in the table above.
|
Revenues
The following table sets forth supplemental revenue information
for the three months ended June 30, ($ in millions):
|
2019
|
|
2018
|
|
% Change
2018-2019
|
Medicaid
|
$
|
12,119
|
|
|
$
|
8,919
|
|
|
36
|
%
|
Commercial
|
3,872
|
|
|
3,143
|
|
|
23
|
%
|
Medicare
(1)
|
1,465
|
|
|
1,203
|
|
|
22
|
%
|
Other
|
900
|
|
|
916
|
|
|
(2)
|
%
|
Total
Revenues
|
$
|
18,356
|
|
|
$
|
14,181
|
|
|
29
|
%
|
|
(1)
|
Medicare includes
Medicare Advantage, Medicare Supplement, Special Needs Plans, and
MMP.
|
Statement of Operations: Three Months Ended June 30,
2019
- For the second quarter of 2019, total revenues increased 29% to
$18.4 billion from $14.2 billion in the comparable period in 2018.
The increase over the prior year was primarily due to the
acquisition of Fidelis Care, growth
in the Health Insurance Marketplace business, expansions and new
programs in many of our states in 2018 and 2019, particularly
Arkansas, New Mexico, and Pennsylvania. These increases were partially
offset by the health insurer fee moratorium in 2019.
- Sequentially, total revenues decreased 1% from the first
quarter of 2019 primarily due to significant pass through payments
from the States of California and
New York in the first
quarter.
- HBR of 86.7% for the second quarter of 2019 represents an
increase from 85.7% in the comparable period in 2018. The increase
was primarily attributable to the Health Insurance Marketplace
business where margins have normalized, as expected, from the
favorable performance in 2018. The increase was also due to the
health insurer fee moratorium and the acquisition of Fidelis Care, which operates at a higher
HBR.
- HBR increased sequentially from 85.7% in the first quarter of
2019. The increase was primarily due to the normal seasonality in
the Health Insurance Marketplace business.
- The SG&A expense ratio was 9.1% for the second quarter of
2019, compared to 9.6% in the second quarter of 2018. The Adjusted
SG&A expense ratio was 9.0% for the second quarter of 2019,
compared to 9.6% in the second quarter of 2018. The SG&A and
Adjusted SG&A expense ratios both decreased due to the
acquisition of Fidelis Care, which
operates at a lower SG&A expense ratio.
- The effective tax rate was 25.7% for the second quarter of
2019, compared to 36.9% in the second quarter of 2018. The decrease
in the effective tax rate was due to the impact of the health
insurer fee moratorium.
Balance Sheet
At June 30, 2019, the Company had cash, investments and
restricted deposits of $15.9 billion,
including $801 million held by
unregulated entities. Medical claims liabilities totaled
$7.4 billion. The Company's days in
claims payable was 47 days, which is a decrease of one day over the
first quarter of 2019. Total debt was $7.1
billion, which includes $513
million of borrowings on our $2.0
billion revolving credit facility at quarter end. The debt
to capitalization ratio was 36.3% at June 30, 2019, excluding
$158 million of non-recourse
debt.
Outlook
The Company's annual guidance for 2019 has been updated to
reflect the second quarter performance and the reinvestment of
$0.05 per diluted share in Centene
Forward related initiatives in the second half of 2019.
|
|
Full Year
2019
|
|
|
|
Low
|
|
High
|
|
Total revenues (in
billions)
|
|
$
|
73.6
|
|
|
$
|
74.2
|
|
|
GAAP diluted
EPS
|
|
$
|
3.70
|
|
|
$
|
3.87
|
|
|
Adjusted Diluted EPS
(1)
|
|
$
|
4.29
|
|
|
$
|
4.49
|
|
|
HBR
|
|
86.6
|
%
|
|
87.1
|
%
|
|
SG&A expense
ratio
|
|
9.2
|
%
|
|
9.7
|
%
|
|
Adjusted SG&A
expense ratio (2)
|
|
9.1
|
%
|
|
9.6
|
%
|
|
Effective tax
rate
|
|
24.5
|
%
|
|
26.5
|
%
|
|
Diluted shares
outstanding (in millions)
|
|
420.5
|
|
|
421.5
|
|
|
|
|
|
|
|
|
|
|
(1)
|
Adjusted Diluted EPS
excludes amortization of acquired intangible assets of $0.46 to
$0.47 per diluted share and acquisition related expenses of $0.13
to $0.15 per diluted share.
|
|
|
(2)
|
Adjusted SG&A
expense ratio excludes acquisition related expenses of $73 million
to $84 million.
|
Conference Call
As previously announced, the Company will host a conference call
Tuesday, July 23, 2019, at approximately 8:30 AM (Eastern Time) to review the financial
results for the second quarter ended June 30,
2019. Michael Neidorff and Jeffrey
Schwaneke will host the conference call.
Investors and other interested parties are invited to listen to
the conference call by dialing 1-877-883-0383 in the U.S. and
Canada; +1-412-902-6506 from
abroad, including the following Elite Entry Number: 9467577 to
expedite caller registration; or via a live, audio webcast on the
Company's website at www.centene.com, under the Investors
section.
A webcast replay will be available for on-demand listening
shortly after the completion of the call for the next twelve months
or until 11:59 PM (Eastern Time) on
Tuesday, July 21, 2020, at the aforementioned URL. In
addition, a digital audio playback will be available until
9:00 AM (Eastern Time) on Tuesday,
July 30, 2019, by dialing 1-877-344-7529 in the U.S. and
Canada, or +1-412-317-0088 from
abroad, and entering access code 10132753.
Non-GAAP Financial Presentation
The Company is providing certain non-GAAP financial measures in
this release as the Company believes that these figures are helpful
in allowing investors to more accurately assess the ongoing nature
of the Company's operations and measure the Company's performance
more consistently across periods. The Company uses the presented
non-GAAP financial measures internally to allow management to focus
on period-to-period changes in the Company's core business
operations. Therefore, the Company believes that this information
is meaningful in addition to the information contained in the GAAP
presentation of financial information. The presentation of this
additional non-GAAP financial information is not intended to be
considered in isolation or as a substitute for the financial
information prepared and presented in accordance with GAAP.
Specifically, the Company believes the presentation of non-GAAP
financial information that excludes amortization of acquired
intangible assets and acquisition related expenses, as well as
other items, allows investors to develop a more meaningful
understanding of the Company's performance over time. The tables
below provide reconciliations of non-GAAP items ($ in millions,
except per share data):
|
Three Months Ended
June 30,
|
|
Six Months Ended
June 30,
|
|
2019
|
|
2018
|
|
2019
|
|
2018
|
GAAP net earnings
attributable to Centene
|
$
|
495
|
|
|
$
|
300
|
|
|
$
|
1,017
|
|
|
$
|
640
|
|
Amortization of
acquired intangible assets
|
64
|
|
|
45
|
|
|
129
|
|
|
84
|
|
Acquisition related
expenses
|
23
|
|
|
1
|
|
|
41
|
|
|
22
|
|
Other adjustments
(1)
|
—
|
|
|
30
|
|
|
—
|
|
|
30
|
|
Income tax effects of
adjustments (2)
|
(21)
|
|
|
(16)
|
|
|
(41)
|
|
|
(30)
|
|
Adjusted net
earnings
|
$
|
561
|
|
|
$
|
360
|
|
|
$
|
1,146
|
|
|
$
|
746
|
|
|
|
(1)
|
Other adjustments
include the 2018 impact of retroactive changes to the California
minimum medical loss ratio (MLR) of $30 million of
expense.
|
|
|
(2)
|
The income tax
effects of adjustments are based on the effective income tax rates
applicable to adjusted (non-GAAP) results.
|
|
Three Months
Ended
June 30,
|
|
Six Months
Ended
June 30,
|
|
Annual
Guidance
December 31, 2019
|
|
2019
|
|
2018
|
|
2019
|
|
2018
|
|
GAAP diluted EPS
attributable to Centene
|
$
|
1.18
|
|
|
$
|
0.75
|
|
|
$
|
2.42
|
|
|
$
|
1.70
|
|
|
$3.70 -
$3.87
|
Amortization of
acquired intangible assets (1)
|
0.12
|
|
|
0.09
|
|
|
0.24
|
|
|
0.17
|
|
|
$0.46 -
$0.47
|
Acquisition related
expenses (2)
|
0.04
|
|
|
—
|
|
|
0.07
|
|
|
0.05
|
|
|
$0.13 -
$0.15
|
Other adjustments
(3)
|
—
|
|
|
0.06
|
|
|
—
|
|
|
0.06
|
|
|
—
|
Adjusted Diluted
EPS
|
$
|
1.34
|
|
|
$
|
0.90
|
|
|
$
|
2.73
|
|
|
$
|
1.98
|
|
|
$4.29 -
$4.49
|
|
|
(1)
|
The amortization of
acquired intangible assets per diluted share presented above is net
of an income tax benefit of $0.04 and $0.02 for the three months
ended June 30, 2019 and 2018, respectively, and $0.07 and
$0.05 for the six months ended June 30, 2019 and 2018,
respectively, and an estimated $0.14 for the year ended December
31, 2019.
|
|
|
(2)
|
The acquisition
related expenses per diluted share presented above are net of an
income tax benefit of $0.01 for the three months ended
June 30, 2019, and $0.03 and $0.01 for the six months ended
June 30, 2019 and 2018, respectively, and an estimated $0.05
for the year ended December 31, 2019.
|
|
|
(3)
|
Other adjustments
include the 2018 impact of retroactive changes to the California
MLR, which is net of an income tax benefit of $0.02 per
diluted share for both the three and six months ended June 30,
2018.
|
|
Three Months Ended
June 30,
|
|
Six Months Ended
June 30,
|
|
2019
|
|
2018
|
|
2019
|
|
2018
|
GAAP SG&A
expenses
|
$
|
1,574
|
|
|
$
|
1,237
|
|
|
$
|
3,183
|
|
|
$
|
2,553
|
|
Acquisition related
expenses
|
21
|
|
|
1
|
|
|
38
|
|
|
22
|
|
Adjusted SG&A
expenses
|
$
|
1,553
|
|
|
$
|
1,236
|
|
|
$
|
3,145
|
|
|
$
|
2,531
|
|
About Centene Corporation
Centene Corporation, a Fortune 100 company, is a diversified,
multi-national healthcare enterprise that provides a portfolio of
services to government sponsored and commercial healthcare
programs, focusing on under-insured and uninsured individuals. Many
receive benefits provided under Medicaid, including the State
Children's Health Insurance Program (CHIP), as well as Aged, Blind
or Disabled (ABD), Foster Care and
Long-Term Services and Supports (LTSS), in addition to other
state-sponsored programs, Medicare (including the Medicare
prescription drug benefit commonly known as "Part D"), dual
eligible programs and programs with the U.S. Department of Defense.
Centene also provides healthcare services to groups and individuals
delivered through commercial health plans. Centene operates local
health plans and offers a range of health insurance solutions. It
also contracts with other healthcare and commercial organizations
to provide specialty services including behavioral health
management, care management software, correctional healthcare
services, dental benefits management, commercial programs,
home-based primary care services, life and health management,
vision benefits management, pharmacy benefits management, specialty
pharmacy and telehealth services.
Centene uses its investor relations website to publish important
information about the Company, including information that may be
deemed material to investors. Financial and other information about
Centene is routinely posted and is accessible on Centene's investor
relations website, http://www.centene.com/investors.
Forward-Looking Statements
All statements, other than statements of current or
historical fact, contained in this press release are
forward-looking statements. Without limiting the foregoing,
forward-looking statements often use words such as "believe,"
"anticipate," "plan," "expect," "estimate," "intend," "seek,"
"target," "goal," "may," "will," "would," "could," "should," "can,"
"continue" and other similar words or expressions (and the negative
thereof). Centene (the Company, our, or we) intends such
forward-looking statements to be covered by the safe-harbor
provisions for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995, and we are including this
statement for purposes of complying with these safe-harbor
provisions. In particular, these statements include, without
limitation, statements about our future operating or financial
performance, market opportunity, growth strategy, competition,
expected activities in completed and future acquisitions, including
statements about the impact of our proposed acquisition (the
WellCare Transaction) of WellCare Health Plans, Inc. (WellCare),
our recent acquisition (the Fidelis Care Acquisition) of
substantially all the assets of New York
State Catholic Health Plan, Inc., d/b/a Fidelis Care New
York ( Fidelis Care), investments and the adequacy of our available
cash resources. These forward-looking statements reflect our
current views with respect to future events and are based on
numerous assumptions and assessments made by us in light of our
experience and perception of historical trends, current conditions,
business strategies, operating environments, future developments
and other factors we believe appropriate. By their nature,
forward-looking statements involve known and unknown risks and
uncertainties and are subject to change because they relate to
events and depend on circumstances that will occur in the future,
including economic, regulatory, competitive and other factors that
may cause our or our industry's actual results, levels of activity,
performance or achievements to be materially different from any
future results, levels of activity, performance or achievements
expressed or implied by these forward-looking
statements. These statements are not guarantees of future
performance and are subject to risks, uncertainties and
assumptions. All forward-looking statements included in this press
release are based on information available to us on the date
hereof. Except as may be otherwise required by law, we undertake no
obligation to update or revise the forward-looking statements
included in this press release, whether as a result of new
information, future events or otherwise, after the date
hereof. You should not place undue reliance on any forward-looking
statements, as actual results may differ materially from
projections, estimates, or other forward-looking statements due to
a variety of important factors, variables and events including but
not limited to: the risk that regulatory or other approvals
required for the WellCare Transaction may be delayed or not
obtained or are obtained subject to conditions that are not
anticipated that could require the exertion of management's time
and our resources or otherwise have an adverse effect on us; the
possibility that certain conditions to the consummation of the
WellCare Transaction will not be satisfied or completed on a timely
basis and, accordingly, the WellCare Transaction may not be
consummated on a timely basis or at all; uncertainty as to the
expected financial performance of the combined company following
completion of the WellCare Transaction; the possibility that the
expected synergies and value creation from the WellCare Transaction
will not be realized, or will not be realized within the expected
time period; the exertion of management's time and the Company's
resources, and other expenses incurred and business changes
required, in connection with any regulatory, governmental or third
party consents or approvals for the WellCare Transaction; the risk
that unexpected costs will be incurred in connection with the
completion and/or integration of the WellCare Transaction or that
the integration of WellCare will be more difficult or time
consuming than expected; the risk that potential litigation in
connection with the WellCare Transaction may affect the timing or
occurrence of the WellCare Transaction, cause it not to close at
all, or result in significant costs of defense, indemnification and
liability; unexpected costs, charges or expenses resulting from the
WellCare Transaction; the possibility that competing offers will be
made to acquire WellCare; the inability to retain key personnel;
disruption from the announcement, pendency and/or completion of the
WellCare Transaction, including potential adverse reactions or
changes to business relationships with customers, employees,
suppliers or regulators, making it more difficult to maintain
business and operational relationships; the risk that, following
the WellCare Transaction, the combined company may not be able to
effectively manage its expanded operations; our ability to
accurately predict and effectively manage health benefits and other
operating expenses and reserves; competition; membership and
revenue declines or unexpected trends; changes in healthcare
practices, new technologies, and advances in medicine; increased
healthcare costs; changes in economic, political or market
conditions; changes in federal or state laws or regulations,
including changes with respect to income tax reform or government
healthcare programs as well as changes with respect to the Patient
Protection and Affordable Care Act and the Health Care and
Education Affordability Reconciliation Act, collectively referred
to as the Affordable Care Act (ACA) and any regulations enacted
thereunder that may result from changing political conditions or
judicial actions, including the ultimate outcome of the District
Court decision in "Texas v. United States
of America" regarding the constitutionality of the ACA; rate
cuts or other payment reductions or delays by governmental payors
and other risks and uncertainties affecting our government
businesses; our ability to adequately price products on federally
facilitated and state-based Health Insurance Marketplaces; tax
matters; disasters or major epidemics; the outcome of legal and
regulatory proceedings; changes in expected contract start dates;
provider, state, federal and other contract changes and timing of
regulatory approval of contracts; the expiration, suspension, or
termination of our contracts with federal or state governments
(including but not limited to Medicaid, Medicare, TRICARE or other
customers); the difficulty of predicting the timing or outcome of
pending or future litigation or government investigations;
challenges to our contract awards; cyber-attacks or other privacy
or data security incidents; the possibility that the expected
synergies and value creation from acquired businesses, including,
without limitation, the Fidelis Care Acquisition, will not be
realized, or will not be realized within the expected time
period; the exertion of management's time and our resources,
and other expenses incurred and business changes required in
connection with complying with the undertakings in connection with
any regulatory, governmental or third party consents or approvals
for acquisitions, including the Fidelis Care Acquisition;
disruption caused by significant completed and pending
acquisitions, including, among others, the Fidelis Care
Acquisition, making it more difficult to maintain business and
operational relationships; the risk that unexpected costs will be
incurred in connection with the completion and/or integration of
acquisition transactions, including among others, the Fidelis Care
Acquisition; changes in expected closing dates, estimated purchase
price and accretion for acquisitions; the risk that acquired
businesses, including Fidelis Care,
will not be integrated successfully; the risk that, following the
Fidelis Care Acquisition, we may not be able to effectively manage
our expanded operations; restrictions and limitations in connection
with our indebtedness; our ability to maintain the Centers for
Medicare and Medicaid Services (CMS) Star ratings and maintain or
achieve improvement in other quality scores in each case that can
impact revenue and future growth; availability of debt and equity
financing, on terms that are favorable to us; inflation; foreign
currency fluctuations; and risks and uncertainties discussed in the
reports that Centene has filed with the Securities and Exchange
Commission. This list of important factors is not intended to be
exhaustive. We discuss certain of these matters more fully, as well
as certain other factors that may affect our business operations,
financial condition and results of operations, in our filings with
the Securities and Exchange Commission (SEC), including the
registration statement on Form S-4 filed by Centene with the SEC on
May 23, 2019, our annual report on
Form 10-K, quarterly reports on Form 10-Q and current reports on
Form 8-K. Due to these important factors and risks, we cannot give
assurances with respect to our future performance, including
without limitation our ability to maintain adequate premium levels
or our ability to control our future medical and selling, general
and administrative costs.
[Tables Follow]
CENTENE
CORPORATION AND SUBSIDIARIES
|
CONSOLIDATED
BALANCE SHEETS
|
(In millions,
except shares in thousands and per share data in
dollars)
|
|
|
June 30,
2019
|
|
December 31,
2018
|
|
(Unaudited)
|
|
|
ASSETS
|
|
|
|
Current
assets:
|
|
|
|
Cash and cash
equivalents
|
$
|
6,875
|
|
|
$
|
5,342
|
|
Premium and trade
receivables
|
5,194
|
|
|
5,150
|
|
Short-term
investments
|
765
|
|
|
722
|
|
Other current
assets
|
762
|
|
|
784
|
|
Total current
assets
|
13,596
|
|
|
11,998
|
|
Long-term
investments
|
7,632
|
|
|
6,861
|
|
Restricted
deposits
|
630
|
|
|
555
|
|
Property, software
and equipment, net
|
1,878
|
|
|
1,706
|
|
Goodwill
|
7,126
|
|
|
7,015
|
|
Intangible assets,
net
|
2,163
|
|
|
2,239
|
|
Other long-term
assets
|
1,343
|
|
|
527
|
|
Total
assets
|
$
|
34,368
|
|
|
$
|
30,901
|
|
|
|
|
|
LIABILITIES,
REDEEMABLE NONCONTROLLING INTERESTS AND STOCKHOLDERS'
EQUITY
|
|
|
|
Current
liabilities:
|
|
|
|
Medical claims
liability
|
$
|
7,447
|
|
|
$
|
6,831
|
|
Accounts payable and
accrued expenses
|
4,032
|
|
|
4,051
|
|
Return of premium
payable
|
834
|
|
|
666
|
|
Unearned
revenue
|
253
|
|
|
385
|
|
Current portion of
long-term debt
|
87
|
|
|
38
|
|
Total current
liabilities
|
12,653
|
|
|
11,971
|
|
Long-term
debt
|
7,047
|
|
|
6,648
|
|
Other long-term
liabilities
|
2,398
|
|
|
1,259
|
|
Total
liabilities
|
22,098
|
|
|
19,878
|
|
Commitments and
contingencies
|
|
|
|
Redeemable
noncontrolling interests
|
22
|
|
|
10
|
|
Stockholders'
equity:
|
|
|
|
Preferred stock,
$0.001 par value; authorized 10,000 shares; no shares issued or
outstanding at June 30, 2019 and December 31, 2018
|
—
|
|
|
—
|
|
Common stock, $0.001
par value; authorized 800,000 shares; 419,319 issued and 413,527
outstanding at June 30, 2019, and 417,695 issued and 412,478
outstanding at December 31, 2018
|
—
|
|
|
—
|
|
Additional paid-in
capital
|
7,531
|
|
|
7,449
|
|
Accumulated other
comprehensive earnings (loss)
|
119
|
|
|
(56)
|
|
Retained
earnings
|
4,680
|
|
|
3,663
|
|
Treasury stock, at
cost (5,792 and 5,217 shares, respectively)
|
(176)
|
|
|
(139)
|
|
Total Centene
stockholders' equity
|
12,154
|
|
|
10,917
|
|
Noncontrolling
interest
|
94
|
|
|
96
|
|
Total stockholders'
equity
|
12,248
|
|
|
11,013
|
|
Total liabilities,
redeemable noncontrolling interests and stockholders'
equity
|
$
|
34,368
|
|
|
$
|
30,901
|
|
CENTENE
CORPORATION AND SUBSIDIARIES
|
CONSOLIDATED
STATEMENTS OF OPERATIONS
|
(In millions,
except shares in thousands and per share data in
dollars)
|
(Unaudited)
|
|
|
Three Months
Ended June 30,
|
|
Six Months
Ended
June 30,
|
|
2019
|
|
2018
|
|
2019
|
|
2018
|
Revenues:
|
|
|
|
|
|
|
|
Premium
|
$
|
16,554
|
|
|
$
|
12,113
|
|
|
$
|
32,757
|
|
|
$
|
24,016
|
|
Service
|
745
|
|
|
762
|
|
|
1,380
|
|
|
1,415
|
|
Premium and service
revenues
|
17,299
|
|
|
12,875
|
|
|
34,137
|
|
|
25,431
|
|
Premium tax and
health insurer fee
|
1,057
|
|
|
1,306
|
|
|
2,663
|
|
|
1,944
|
|
Total
revenues
|
18,356
|
|
|
14,181
|
|
|
36,800
|
|
|
27,375
|
|
Expenses:
|
|
|
|
|
|
|
|
Medical
costs
|
14,354
|
|
|
10,380
|
|
|
28,236
|
|
|
20,419
|
|
Cost of
services
|
615
|
|
|
658
|
|
|
1,159
|
|
|
1,201
|
|
Selling, general and
administrative expenses
|
1,574
|
|
|
1,237
|
|
|
3,183
|
|
|
2,553
|
|
Amortization of
acquired intangible assets
|
64
|
|
|
45
|
|
|
129
|
|
|
84
|
|
Premium tax
expense
|
1,106
|
|
|
1,189
|
|
|
2,765
|
|
|
1,735
|
|
Health insurer fee
expense
|
—
|
|
|
183
|
|
|
—
|
|
|
354
|
|
Total operating
expenses
|
17,713
|
|
|
13,692
|
|
|
35,472
|
|
|
26,346
|
|
Earnings from
operations
|
643
|
|
|
489
|
|
|
1,328
|
|
|
1,029
|
|
Other income
(expense):
|
|
|
|
|
|
|
|
Investment and other
income
|
120
|
|
|
65
|
|
|
219
|
|
|
106
|
|
Interest
expense
|
(101)
|
|
|
(80)
|
|
|
(200)
|
|
|
(148)
|
|
Earnings from
operations, before income tax expense
|
662
|
|
|
474
|
|
|
1,347
|
|
|
987
|
|
Income tax
expense
|
170
|
|
|
175
|
|
|
336
|
|
|
350
|
|
Net
earnings
|
492
|
|
|
299
|
|
|
1,011
|
|
|
637
|
|
Loss attributable
to noncontrolling interests
|
3
|
|
|
1
|
|
|
6
|
|
|
3
|
|
Net earnings
attributable to Centene Corporation
|
$
|
495
|
|
|
$
|
300
|
|
|
$
|
1,017
|
|
|
$
|
640
|
|
|
|
|
|
|
|
|
|
Net earnings per
common share attributable to Centene Corporation:
|
Basic earnings per
common share
|
$
|
1.20
|
|
|
$
|
0.77
|
|
|
$
|
2.46
|
|
|
$
|
1.73
|
|
Diluted earnings per
common share
|
$
|
1.18
|
|
|
$
|
0.75
|
|
|
$
|
2.42
|
|
|
$
|
1.70
|
|
|
|
|
|
|
|
|
|
Weighted average
number of common shares outstanding:
|
|
|
|
|
|
|
|
Basic
|
413,370
|
|
|
391,037
|
|
|
413,144
|
|
|
369,440
|
|
Diluted
|
419,671
|
|
|
398,902
|
|
|
419,707
|
|
|
377,142
|
|
CENTENE
CORPORATION AND SUBSIDIARIES
|
CONSOLIDATED
STATEMENTS OF CASH FLOWS
|
(In
millions)
|
(Unaudited)
|
|
|
Six Months Ended
June 30,
|
|
2019
|
|
2018
|
Cash flows from
operating activities:
|
|
|
|
Net
earnings
|
$
|
1,011
|
|
|
$
|
637
|
|
Adjustments to
reconcile net earnings to net cash provided by operating
activities
|
Depreciation and
amortization
|
313
|
|
|
215
|
|
Stock compensation
expense
|
72
|
|
|
67
|
|
Deferred income
taxes
|
(10)
|
|
|
4
|
|
Changes in assets and
liabilities
|
|
|
|
Premium and trade
receivables
|
234
|
|
|
(553)
|
|
Other
assets
|
(47)
|
|
|
2
|
|
Medical claims
liabilities
|
558
|
|
|
717
|
|
Unearned
revenue
|
(138)
|
|
|
202
|
|
Accounts payable and
accrued expenses
|
(616)
|
|
|
(865)
|
|
Other long-term
liabilities
|
869
|
|
|
865
|
|
Other operating
activities, net
|
(13)
|
|
|
29
|
|
Net cash provided by
operating activities
|
2,233
|
|
|
1,320
|
|
Cash flows from
investing activities:
|
|
|
|
Capital
expenditures
|
(336)
|
|
|
(362)
|
|
Purchases of
investments
|
(1,280)
|
|
|
(1,375)
|
|
Sales and maturities
of investments
|
719
|
|
|
721
|
|
Acquisitions, net of
cash acquired
|
(32)
|
|
|
(237)
|
|
Net cash used in
investing activities
|
(929)
|
|
|
(1,253)
|
|
Cash flows from
financing activities:
|
|
|
|
Proceeds from the
issuance of common stock
|
—
|
|
|
2,780
|
|
Proceeds from
long-term debt
|
5,617
|
|
|
5,146
|
|
Payments of long-term
debt
|
(5,353)
|
|
|
(3,471)
|
|
Common stock
repurchases
|
(37)
|
|
|
(13)
|
|
Purchase of
noncontrolling interest
|
—
|
|
|
(63)
|
|
Other financing
activities, net
|
9
|
|
|
(1)
|
|
Net cash provided by
financing activities
|
236
|
|
|
4,378
|
|
Effect of exchange
rate changes on cash, cash equivalents and restricted
cash
|
2
|
|
|
—
|
|
Net increase in cash,
cash equivalents and restricted cash and cash
equivalents
|
1,542
|
|
|
4,445
|
|
Cash, cash
equivalents, and restricted cash and cash equivalents,
beginning of period
|
5,350
|
|
|
4,089
|
|
Cash, cash
equivalents, and restricted cash and cash equivalents, end of
period
|
$
|
6,892
|
|
|
$
|
8,534
|
|
Supplemental
disclosures of cash flow information:
|
|
|
|
Interest
paid
|
$
|
132
|
|
|
$
|
130
|
|
Income taxes
paid
|
$
|
381
|
|
|
$
|
195
|
|
Equity issued in
connection with acquisitions
|
$
|
—
|
|
|
$
|
507
|
|
|
|
|
|
The following table
provides a reconciliation of cash, cash equivalents, and restricted
cash and cash equivalents reported within the Consolidated Balance
Sheets to the totals above:
|
|
June
30,
|
|
2019
|
|
2018
|
Cash and cash
equivalents
|
$
|
6,875
|
|
|
$
|
6,707
|
|
Restricted cash and
cash equivalents, included in restricted deposits
|
17
|
|
|
1,827
|
|
Total cash, cash
equivalents, and restricted cash and cash equivalents
|
$
|
6,892
|
|
|
$
|
8,534
|
|
CENTENE
CORPORATION
|
SUPPLEMENTAL
FINANCIAL DATA
|
|
|
Q2
|
|
Q1
|
|
Q4
|
|
Q3
|
|
Q2
|
|
2019
|
|
2019
|
|
2018
|
|
2018
|
|
2018
|
MANAGED CARE
MEMBERSHIP BY LINE OF BUSINESS
|
Medicaid:
|
|
|
|
|
|
|
|
|
|
TANF, CHIP &
Foster Care
|
7,388,700
|
|
|
7,491,100
|
|
|
7,356,200
|
|
|
7,260,500
|
|
|
5,852,000
|
|
ABD &
LTSS
|
997,900
|
|
|
1,036,200
|
|
|
1,002,100
|
|
|
964,200
|
|
|
874,200
|
|
Behavioral
Health
|
68,800
|
|
|
56,000
|
|
|
36,500
|
|
|
455,900
|
|
|
454,600
|
|
Total
Medicaid
|
8,455,400
|
|
|
8,583,300
|
|
|
8,394,800
|
|
|
8,680,600
|
|
|
7,180,800
|
|
Commercial
|
2,449,400
|
|
|
2,472,700
|
|
|
1,978,000
|
|
|
2,062,500
|
|
|
2,051,700
|
|
Medicare
(1)
|
398,500
|
|
|
393,900
|
|
|
416,900
|
|
|
417,400
|
|
|
343,800
|
|
International
|
463,100
|
|
|
151,600
|
|
|
151,600
|
|
|
—
|
|
|
—
|
|
Correctional
|
153,900
|
|
|
153,200
|
|
|
151,300
|
|
|
150,900
|
|
|
157,900
|
|
Total at-risk
membership
|
11,920,300
|
|
|
11,754,700
|
|
|
11,092,600
|
|
|
11,311,400
|
|
|
9,734,200
|
|
TRICARE
eligibles
|
2,855,800
|
|
|
2,855,800
|
|
|
2,858,900
|
|
|
2,858,900
|
|
|
2,851,500
|
|
Non-risk
membership
|
228,100
|
|
|
211,900
|
|
|
219,700
|
|
|
219,000
|
|
|
218,100
|
|
Total
|
15,004,200
|
|
|
14,822,400
|
|
|
14,171,200
|
|
|
14,389,300
|
|
|
12,803,800
|
|
|
|
|
|
|
|
|
|
|
|
(1) Membership
includes Medicare Advantage, Medicare Supplement, Special Needs
Plans, and MMP.
|
|
|
|
|
|
|
|
|
|
|
NUMBER OF
EMPLOYEES
|
52,000
|
|
|
48,100
|
|
|
47,300
|
|
|
45,400
|
|
|
41,200
|
|
|
|
|
|
|
|
|
|
|
|
DAYS IN CLAIMS
PAYABLE (2)
|
47
|
|
|
48
|
|
|
48
|
|
|
51
|
|
|
44
|
|
(2) Days in claims
payable is a calculation of medical claims liabilities at the end
of the period divided by average claims expense per calendar day
for such period.
|
|
|
|
|
|
|
|
|
|
|
CASH, INVESTMENTS
AND RESTRICTED DEPOSITS (in millions)
|
Regulated
|
$
|
15,101
|
|
|
$
|
14,303
|
|
|
$
|
13,002
|
|
|
$
|
13,782
|
|
|
$
|
11,455
|
|
Unregulated
|
801
|
|
|
507
|
|
|
478
|
|
|
481
|
|
|
3,543
|
|
Total
|
$
|
15,902
|
|
|
$
|
14,810
|
|
|
$
|
13,480
|
|
|
$
|
14,263
|
|
|
$
|
14,998
|
|
|
|
|
|
|
|
|
|
|
|
DEBT TO
CAPITALIZATION
|
36.8
|
%
|
|
36.9
|
%
|
|
37.8
|
%
|
|
37.3
|
%
|
|
37.0
|
%
|
DEBT TO
CAPITALIZATION EXCLUDING NON-RECOURSE DEBT
(3)
|
36.3
|
%
|
|
36.5
|
%
|
|
37.4
|
%
|
|
36.9
|
%
|
|
36.7
|
%
|
(3) The non-recourse
debt represents the Company's mortgage note payable ($56 million at
June 30, 2019) and construction loan payable ($102 million at June
30, 2019).
|
Debt to
capitalization is calculated as follows: total debt divided by
(total debt + total equity).
|
OPERATING RATIOS
|
Three Months Ended
June 30,
|
|
Six Months Ended
June 30,
|
|
2019
|
|
2018
|
|
2019
|
|
2018
|
HBR
|
86.7
|
%
|
|
85.7
|
%
|
|
86.2
|
%
|
|
85.0
|
%
|
SG&A expense
ratio
|
9.1
|
%
|
|
9.6
|
%
|
|
9.3
|
%
|
|
10.0
|
%
|
Adjusted SG&A
expense ratio
|
9.0
|
%
|
|
9.6
|
%
|
|
9.2
|
%
|
|
10.0
|
%
|
MEDICAL CLAIMS LIABILITY
The changes in medical claims liability are summarized as
follows (in millions):
Balance, June 30,
2018
|
|
$
|
5,003
|
Less: reinsurance
recoverable
|
|
17
|
Balance, June 30,
2018, net
|
|
4,986
|
Acquisitions and
purchase accounting adjustments
|
|
1,265
|
Less: acquired
reinsurance recoverable
|
|
8
|
Incurred related
to:
|
|
|
Current
period
|
|
54,382
|
Prior period
(1)
|
|
(508)
|
Total
incurred
|
|
53,874
|
Paid related
to:
|
|
|
Current
period
|
|
48,506
|
Prior
period
|
|
4,183
|
Total paid
|
|
52,689
|
Balance, June 30,
2019, net
|
|
7,428
|
Plus: reinsurance
recoverable
|
|
19
|
Balance, June 30,
2019
|
|
$
|
7,447
|
|
(1) Incurred related
to prior period does not include development on the acquired
Fidelis Care medical claims liability as we closed that acquisition
on July 1, 2018. Our Form 10-Q presents a rollforward for the six
months ended June 30, 2019, which includes the development on
Fidelis Care reserves, subsequent to the acquisition.
|
Centene's claims reserving process utilizes a consistent
actuarial methodology to estimate Centene's ultimate liability. Any
reduction in the "Incurred related to: Prior period" amount may be
offset as Centene actuarially determines "Incurred related to:
Current period." As such, only in the absence of a consistent
reserving methodology would favorable development of prior period
claims liability estimates reduce medical costs. Centene believes
it has consistently applied its claims reserving methodology.
Additionally, approximately $68
million was recorded as a decrease to premium revenues
resulting from development within "Incurred related to: Prior
period" due to minimum HBR and other return of premium
programs.
The amount of the "Incurred related to: Prior period" above
represents favorable development and includes the effects of
reserving under moderately adverse conditions, new markets where we
use a conservative approach in setting reserves during the initial
periods of operations, receipts from other third party payors
related to coordination of benefits and lower medical utilization
and cost trends for dates of service June 30, 2018, and
prior.
View original
content:http://www.prnewswire.com/news-releases/centene-corporation-reports-2019-second-quarter-results-and-increases-2019-guidance-300889128.html
SOURCE Centene Corporation